Puretech Health Share Discussion Threads

[brianblu] 27/11/2024 21:21

Don’t understand those 2 rns sold then re bought (surely not) up 12% stateside

[colinblackbourn] 27/11/2024 08:41

Puretech is staying in the FTSE 250 I believe.

[rogers10] 26/11/2024 12:11

Traders closing positions?

[takeiteasy] 26/11/2024 11:39

seems to be in a rinse and repeat daily pattern of morning sell offs and a late dash at the end of the day to retrieve things - done this for a while ...imvho

[colinblackbourn] 23/11/2024 12:13

Jeffries will have had multiple one to one meetings during the three days of their conference.

[takeiteasy] 23/11/2024 10:43

"PureTech Health certainly appears significantly undervalued. However, for a traditional investor looking at earnings multiples or dividend yield, valuing PureTech is tricky. As with many biotech companies, there is little revenue and substantial annual losses, and it's unclear how an investor will realise this value. In addition, the recent share tender offer left a perceived overhang, and the shares have been heavily sold off."

I would like to think the firm is addressing this in two specific areas that I can see. Ensure they get a share of recurring sales income from drug developments they sell to big pharma alongside having entities within the group launced via IPOs that have a public rather than private status so analysts can impute direct market values for PRTC's retained % holding rather than rely on estimates.

Given the scale of undervaluation has been shown by a number of analysts to be so great any hint now of a plan or path to addressing this MAY be enough for a rethink of the opportunity (choose words carefully here)

I would like us to become more like the BG USA trust model of a public and private equity split within the portfolio :) nai etc

[takeiteasy] 23/11/2024 10:32

"We're very pleased with Seaport's $225 million Series B financing. Led by a syndicate of top-tier investors, this milestone highlights the significant progress we're making across our portfolio. The strong support from this stellar investor group not only reinforces the value generated by our unique R&D engine but also underscores our commitment to advancing transformative therapies for patients. As we look ahead to the upcoming data readout for our internal LYT-100 (deupirfenidone) program, we're excited to continue driving innovation across our portfolio with the goal of delivering impactful treatments that address significant medical needs."

I think there have been 3 triggers in rapid succession: Seaport financing showing much higher valuations, 2 failed trials for major rival for Karuna treatment and suggestions of higher pharmacy income than first thought (posts 2540, 2551 and 2554) and the hope that LYT-100 will also perform well in trial results due very shortly.

Given the extreme bearishness here over many years, a proverbial kick up the backside has been required to inject some life and hope back in - hopefully the above is enough to get us back to a more normalised valuation....nai etc

[hatfullofsky] 23/11/2024 09:53

Nice rise, any thoughts on why ?

[ohisay] 22/11/2024 16:05

Edward some of us aint going to be here next decade !

In the words of the song ..I want it all I want it now,
But a nice journey as they say .

[edwardt] 22/11/2024 16:00

i think they should syndicate that at first opportunity and then we can sit back and await the cashflow over the next decade.

[ohisay] 22/11/2024 13:44

Yes thats why I topped up yesterday ..went through the numbers again and thought the risk reward well in our favour.
I will hold for a bid if LYT 100 has a good outcome this Qtr.

[edwardt] 22/11/2024 12:20

cobenfy = i get £300m npv with updated goldman numbers applying a 20% tax and 15% discount rate.

[kingston78] 22/11/2024 10:22

220 p is my short term target for this share.

[ohisay] 21/11/2024 14:12

Yes its on the low side .
Edit ...
Liberum had it at £1.20

[takeiteasy] 21/11/2024 09:04

"PureTech, listed nine years ago, founded and sold Karuna Therapeutics for $14 billion, has demonstrated an 80% success rate in clinical trials, and has a portfolio of over 25 drug candidates, with multiple opportunities to drive more value. With a large cash balance, it is in a stronger position than ever, allowing it to advance programs further before requiring dilutive external funding. In our view, PureTech should be launching another buyback and not issuing shares at anything less than £4 or $50....Additionally, we believe that PureTech is more of a stock for generalist investors looking for diversified biotech exposure rather than specialists who tend to prefer more focused investments". - this seems a fair summary to me.


I am absolutely no expert but the LYT-100 assessment seems rather conservative against other things I have read (nai etc)

[ohisay] 21/11/2024 08:38

Summary Valuation in the Calvine note ..

Per Share £
Cash end Year 2024 1.14
Seaport 1.06
Vedanta .90
LYT 100 .50
Gallop .17
Rest .66
Total 4.43

Just added FWIW.

[edwardt] 21/11/2024 08:36

Post below mine

[biopharmaguy] 21/11/2024 07:23

Sorry, what is a decent read? Is there a link?

[edwardt] 20/11/2024 19:45

Decent read - think he is way low balling cobenfy npv

[edwardt] 19/11/2024 11:12

possibly but you would have thought schizophrenia cannot be cured by exercise or taking lSD as he would suggest!

[ohisay] 18/11/2024 16:26

RFK effect ?

[hatfullofsky] 18/11/2024 11:20

Give it a couple of months

[edwardt] 18/11/2024 11:19

well my timing was useless!